Ipilimumab in the treatment of metastatic melanoma: A summary of recent studies

Research output: Contribution to journalArticle

Abstract

In the last 20 years, the survival and quality of life outcomes for patients with metastatic melanoma have been poor, with unsatisfactory results of chemotherapy and immunotherapy-based regimens. No drug or combination of drugs had any impact on survival until 2011, when ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4), was approved for clinical use. Phase III trials have shown, for the first time ever, an overall survival benefit of ipilimumab compared with standard treatment, with a manageable toxicity profile. This review will discuss the mechanism of action of ipilimumab and the clinical trials that led to its approval. Copyright - Il Pensiero Scientifico Editore.

Original languageEnglish
JournalTumori
Volume99
Issue number6
DOIs
Publication statusPublished - Nov 2013

Keywords

  • Anti-CTLA-4
  • Immunotherapy
  • Ipilimumab
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Ipilimumab in the treatment of metastatic melanoma: A summary of recent studies'. Together they form a unique fingerprint.

  • Cite this